3 Stocks Pushing The Health Care Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 16,492 as of Wednesday, May 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,744 issues advancing vs. 1,239 declining with 163 unchanged.

The Health Care sector currently sits down 1.4% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the sector include Perrigo ( PRGO), down 8.4%, Incyte ( INCY), down 3.2%, Vertex Pharmaceuticals ( VRTX), down 2.5%, Actavis ( ACT), down 1.6% and Bristol-Myers Squibb Company ( BMY), down 1.4%. Top gainers within the sector include Herbalife ( HLF), up 4.3%, AbbVie ( ABBV), up 2.9%, UnitedHealth Group ( UNH), up 1.8%, WellPoint ( WLP), up 1.7% and Aetna ( AET), up 1.6%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Regeneron Pharmaceuticals is down $4.82 (-1.7%) to $286.01 on light volume. Thus far, 437,471 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $284.53-$294.49 after having opened the day at $291.51 as compared to the previous trading day's close of $290.83.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $29.3 billion and is part of the drugs industry. Shares are up 5.7% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round